Stay updated on Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2; removed the funding-status notice and related topic links (Lung cancer and MedlinePlus Genetics), and removed Revision: v3.4.1.SummaryDifference0.6%

- Check21 days agoChange DetectedSite-wide notice about a lapse in government funding and operating status was added, and the page revision updated to v3.4.1. The core study content and criteria remain unchanged.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded a glossary toggle (Show glossary) and updated UI text, standardizing labels such as 'Last Update Submitted that Met QC Criteria' and capitalization of 'No FEAR Act Data'. The revision/version banner now shows v3.4.0 (replacing v3.3.4); To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedAdded Lung cancer as a topic and related topics including MedlinePlus Genetics. Updated the page revision from v3.3.3 to v3.3.4.SummaryDifference0.2%

- Check49 days agoChange DetectedDeleted Lung cancer and related topics including MedlinePlus Genetics from the study's topics section.SummaryDifference0.2%

- Check56 days agoChange DetectedAdded related topics sections for Lung cancer and MedlinePlus Genetics to the study page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial page.